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Abstract. Malignant hepato-pancreatico-biliary (HPB) tumors have their
highest incidence within the sixth to eighth decades of life. The aging of
the world population has resulted in a dramatic increase in the number of
elderly patients considered for resection of malignant HPB tumors. Be-
cause elderly patients are more likely to have more co-morbidities, cog-
nitive impairment, and decreased life expectancy, the benefit and
appropriateness of these procedures must be scrutinized for geriatric
patients. Therefore, many surgeons have compared the perioperative and
long-term outcome of hepatic and pancreatic resections for elderly and
younger patients. In most series the elderly population was defined by an
age of 70 years or older. The results demonstrate that hepatic resection
for hepatocellular carcinoma and colorectal liver metastases can be safely
performed in well-selected elderly patients with long-term outcome
comparable to younger patients. Similar findings are also reported for
pancreatic resection in elderly patients with either ampullary or pan-
creatic cancer. Although the survival benefit of pancreatico-duodenecto-
my is limited in all age groups, the absence of competitive therapy jus-
tifies this procedure as the sole curative option in younger as well as older
patients. Data on resection of gallbladder cancer and hilar bile duct
cancer in the elderly are sparse, but there is evidence from large series on
resection of these types of tumors that advanced age per se is not a risk
factor for reduced outcome. Therefore, surgical options should not be
denied to elderly patients with a malignant HPB tumor, and the evalu-
ation should include surgeons expert in HPB surgery.
Life expectancy in developed nations increased dramatically over
the 20th century as a result of improvements in working condi-
tions, nutrition, public health, and medicine (Fig. 1). In 1900, life
expectancy at birth was 47.8 years in the United States [1]. In
2001, approximately 100 years later, it was 77.2 years in the
United States, 78.8 years in Europe, and 80.9 years in Japan [1, 2].
This development has resulted in an increase in the older popu-
lation, reflected by the fast-growing age segments ‡ 65 years and ‡
85 years (Fig. 2). While the age group ‡ 65 years comprised only
4.1% (3.1 million persons) of the total U.S. population in 1900, it
reached 12.7% (34.8 million persons) in 2000 [3]. Thus, the
population of this age segment has grown eightfold in the last
century. This trend of aging will continue for the next decades.
Projections predict that the age group ‡ 65 years will increase to
70.3 million persons by 2030, representing 20.0% of total U.S.
population. Similar aging profiles are observed for Europe and
Japan.
Malignant hepato-pancreatico-biliary (HPB) tumors have their
highest incidence within the sixth to the eighth decades of life
(Fig. 3). The median age at diagnosis of a malignant HPB tumor
in the United States was, except for male patients with hepato-
cellular carcinoma, 70 years or older, implying that more than
50% of patients with hepatocellular carcinoma (female patients),
gallbladder, bile duct, and pancreatic cancer are over 70 years old
[4] (Table 1). Similar aging profiles are also observed for colo-
rectal liver metastases. The median age at diagnosis for colorectal
cancer was 72 years (male 70 years, female 74 years). Because
most liver metastases (70%) present as metachronous lesions [5,
6], it is evident that the median age at diagnosis of a patient with
colorectal liver metastases is over 72 years.
Surgical resection is the only potentially curative treatment
option for most types of malignant HPB tumors as far as the
disease is resectable and limited. The aging of the population and
the peak incidence of malignant HPB tumors in the age segment
65–85 years have resulted in a dramatic increase in the number of
elderly patients considered for resection of these tumors (Fig. 2
and 3). Unfortunately, many physicians consider advanced age to
be a contraindication for surgery, for fear that extended resec-
tions of HPB tumors are too risky, with only limited survival
benefit for elderly patients. Surgery is often not offered to these
patients, who are not presented to experienced HPB surgeons,
and as a consequence they receive either no treatment or inap-
propriate treatment. The question therefore arises whether ad-
vanced age represents a risk factor for inadequate treatment of
malignant HPB tumors. For breast cancer, it was reported that
elderly patients are more likely to receive inadequate treatment
even if co-morbidities and functional status are controlled [7, 8].
One inappropriately applied argument for the aged-biased
treatment decision might be the lower life expectancy of elderly
patients compared to younger patients. However, the actual life
expectancy in the United States in 2001 of a person at 65 years
and 75 years of age was still 18.1 years and 11.5 years, respectively
[9]. These demographic data alone should justify offering ade-
quate treatments for elderly patients with malignant HPB tumors
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as long as the disease is limited and co-morbidities and functional
status are controlled.
Another important issue that may influence future treatment
decisions in elderly patients in many health care systems is the
need to control costs. This consideration is of special relevance
for HPB surgery because liver and pancreatic resections are
among the most expensive abdominal surgical procedures. The
rising economic pressure on health care costs raises the question
of how much of health care resources should be allocated to the
older population. This question is being intensively debated, and
it is likely to become one of the most controversial aspects of
health care delivery [10].
This editorial update review analyzes studies on elderly patients
who have undergone surgical resection of malignant HPB tumors.
Perioperative and long-term outcomes were compared between
elderly and younger patients to assess the risk und benefit of
Fig. 2. Actual and projected estimates of the total population (A) and
percentage (B) of age segments ‡ 65 years (65+) and ‡ 85 years (85+) in
the United States [3]. Data of the period 2000–2050 represent middle-
series projections (gray area). All data refer to the resident US
population.
Fig. 3. Age distribution of incidence of 10,395 liver and bile duct
carcinoma cases, 18,790 pancreatic cancer cases, and 91,850 colorectal
cancer cases in the United States during the period 1997–2001. Data
extracted from the Surveillance, Epidemiology, and End Results (SEER)
Program of the National Cancer Institute for the period 1997–2001 [4].
Fig. 1. Estimated life expectancy at birth in the United States from 1900
to 2001. Data extracted from the National Vital Statistics Reports 2004
[1].
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surgical resection of malignant HPB tumors in elderly patients.
The analysis are presented separately for resection of hepato-
cellular carcinoma (HCC), colorectal liver metastases (CLM),
pancreatic and ampullary carcinomas, gallbladder cancer, and
hilar cholangiocarcinoma.
Liver Resection for Hepatocellular Carcinoma
Approximately 427,000 patients die annually from HCC, which
ranks HCC as the 4th most common cause of death from cancer
worldwide [11]. Surgical resection is the preferred standard
treatment for HCC, as long as the tumor is resectable, the disease
limited, and the hepatic function preserved. The peak incidence
of HCC around the 6th decade of life, combined with the aging of
the world population, results in a dramatically increasing elderly
population of patients with HCC considered for hepatic resection.
In Asia, HCC is a major problem, with more than 326,000 deaths
annually, which corresponds to 76% of all HCC-related deaths
worldwide [11]. These demographic data indicate that the greatest
experience with hepatic resection for HCC in elderly patients is in
Asia. Therefore it is not surprising that 10 of 11 identified studies
comparing risk and benefit of hepatic resection for HCC between
young and elderly patients are from Asia [12–21] (Table 2). The
only European study, which is published in the current issue of
the World Journal of Surgery, comes from Italy [22].
Most of the studies analyzed here compared the outcome of
hepatic resection in patients younger and older than 70 years of
age [14, 16–18, 20–22]. Most patient characteristics were homo-
geneously distributed between younger and older patients, but the
elderly patients had significantly lower hepatitis B (HBV) and
higher hepatitis C (HCV) infection rates, as well as higher pro-
portions of female patients (Tables 2, 3) suggesting a different
hepato-carcinogenesis in geriatric patients [28, 29].
Operative data demonstrated similar operative times and blood
loss for older and younger patients [13–16, 20, 21]. Yeh et al.
reported even a significantly lower mean blood loss in elderly
patients [18]. Although the older patients had more co-morbidi-
ties, this had no impact on the postoperative complication rates,
which were similar in the two groups. Interestingly, the Italian
study observed significantly fewer complications in elderly pa-
tients [22]. Mortality rates of 3%–43% are reported for elderly
patients after hepatectomy for HCC (Table 2). Two Asian studies
had an unacceptably high mortality rate of greater than 40% for
elderly patients [13, 14]. However, mortality rates reported in the
recently published cohort studies of the past five years were below
10% and were not significantly different between elderly and
young patients (Table 2). These data underscore that hepatic
resections for HCC can be safely performed in elderly patients
with comparable risk with younger patients. This seems to be true
even for octogenarians [15].
Regarding long-term outcome, there was a large range of 5-
year survival rates in elderly patients ranging between 18% and
76% [12, 15–19, 21, 22]. Cirrhosis and Child-Pugh B/C were
predictors of poor survival in elderly patients, as is proven for the
general patient population [19–21]. Despite the statistical lower
life expectancy of elderly patients, the long-term outcome after
hepatic resection for HCC was comparable between older and
younger patients (Table 3). Furthermore, Hanazaki et al. ob-
served a survival benefit for elderly patients with hepatic recur-
rent disease who underwent repeat hepatic resection [21]. The
favorable perioperative and long-term outcome demonstrates that
selected elderly patients benefit from hepatic resection for HCC
in the same way as younger patients. Therefore, surgical treat-
ment, including extended hepatectomies, is justified in elderly
patients with HCC.
Liver Resection for Colorectal Liver Metastases
Approximately 437,000 patients die annually from colorectal
cancer, which ranks colorectal cancer as the third most common
cause of death from cancer worldwide [11]. The liver is the most
common organ for distant metastases from colorectal cancer,
which is affected in approximately 50%–60% of patients with
colorectal cancer. At present, liver resection is the only curative
therapy option for patients with isolated colorectal liver metas-
tases. Although only 10%–20% of patients with liver metastases
are candidates for surgical resection, as with HCC, the peak
incidence of this disease occurs beyond the age of 70 years, and
the growing life expectancy results in an increasing elderly pop-
ulation considered for hepatic resection. In contrast to HCC, el-
derly patients with colorectal liver metastases represent a
predominantly non-cirrhotic population.
Hepatic resection for colorectal liver metastases in elderly pa-
tients is safe, as demonstrated by a low mortality rate of 3.9%–7.3
% in patients 70 years of age or older (Table 2). When elderly (‡
70 years) and younger (< 70 years) patients were compared,
mortality and complication rates were not significantly different
between both age groups. Interestingly, in one study a subgroup
analysis of patients older than 70 years of age revealed similar
mortality and complication rates for the age segments 70–74
years, 75–79 years, and ‡ 80 years [24]. Despite advanced age,
elderly patients had no prolonged hospital stay compared to that
of younger patients. Although three studies had a selection bias in
terms of a higher frequency of major resections in younger pa-
tients [23, 25, 26], the largest series, by Fong et al., reported an
equivalent distribution of major procedures in young and elderly
patients [24].
Elderly patients had a 5-year overall survival after hepatic
resection of 16–46 months, which was similar to that of younger
patients (Table 4). There is additional evidence from two large
series on hepatic resection for colorectal liver metastases that age
per se is not a risk factor for long-term outcome [30, 31]. These
findings indicate that elderly patients with colorectal liver
metastases benefit from hepatic resection to a similar degree as
younger patients. Therefore, hepatic resection for colorectal liver
metastases should be the preferred therapeutic option for elderly
patients as long as co-morbidities are controlled.
Table 1. Median age at diagnosis of primary malignant hepato-pancrea-
tico-biliary tumors.
Median age (years)
Tumor site Males Females Total
Liver 64 70 66
Gallbladder 73 73 73
Intrahepatic bile duct 71 76 73
Extrahepatic bile ducts 71 74 73
Pancreas 70 74 72
Data from the Surveillance, Epidemiology, and End Results (SEER)
Program of the National Cancer Institute for the period 1997–2001 [4].
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Table 2. Perioperative outcome after hepatic resection for primary and secondary malignant tumors in young and elderly patients.
Author year [ref.]
Underlying
disease
Age
(years)
No. of
patients
Female
(%)
Mortalitiy
rate (%)
Complication
rate (%)
Operative
time (hours)
Blood
loss (ml)
Hospital
stay (days)
Ezaki et al. HCC 56–65 44 11.4 11.4 34.1 — — —
1987 [12] ‡ 66 37 18.9 5.4 24.3 — — —
Yanaga et al. HCC < 65 127 13.4 22.0 21.3 2.7b 3000b —
1988 [13] ‡ 65 27 29.6 40.7 40.7 3.0b 3500b —
Nagasue et al. HCC £ 50 26 — 0.0 26.9 — — —
1993 [19] ‡ 70 32 21.9 12.5 28.1 — — —
Takenaka et al. HCC < 70 229 18.8 0.9 49.8 4.9b 1592b —
1994 [16] ‡ 70 39 30.8 5.1 51.3 4.7b 1560b —
Yamamoto et al. HCC 50–69 40 12.5 5.0a — 4.6b 1718b —
1997 [14] > 70 7 28.6 42.9a — 4.2b 1507b —
Poon et al. HCC < 70 299 14.7a 3.0 40.0 — — —
1999 [17] ‡ 70 31 32.2a 6.0 48.0 — — —
Wu et al. HCC < 80 239 20.5 2.1 15.5 5.5b 1507b 13.5a,b
1999 [15] ‡ 80 21 9.5 0.0 14.3 5.1b 1471b 17.8a,b
Lui et al. HCC < 70 98 16.3 3.1 33.7 6.4b 2710b 16.7b
1999 [20] ‡ 70 24 12.5 8.3 20.8 6.5b 3519b 17.5b
Hanazaki et al. HCC < 70 283 21.5 6.0 23.3 — 1959b —
2000 [21] ‡ 70 103 31.1 9.7 28.2 — 1476b —
Yeh et al. HCC < 70 398 22.1 10.5 — — 1616a,b —
2004 [18] ‡ 70 34 20.6 7.7 — — 1058a,b —
Ferrero et al. HCC £ 70 177 18.1 9.6 42.4a — — 14.8a,b
2005 [22] > 70 64 26.6 3.1 23.4a — — 11.2a,b
Zieren et al. CLM £ 70 72 — 2.8 25.0 — — —
1994 [23] > 70 18 61.1 5.5 27.8 — — 16.0b
Fong et al. CLM < 70 449 43.2 4.2 39.9 — — 12.0a,c
1995 [23] ‡ 70 128 36.7 3.9 42.2 — — 13.0a,c
Brunken et al. CLM < 70 141 — 3.5 26.2 — — 14.0b
1998 [25] ‡ 70 25 — 4.0 28.0 — — 15.0b
Brand et al. CLM < 70 126 — 2.4 30.9 4.7b 1973b 16.6b
2000 [26] ‡ 70 41 — 7.3 39.0 4.0b 1575b 13.1b
Cosenza et al. HCC, CLM, Others < 59 22 50.0 0.0 31.8 — 900c 9.8b
1995 [27] > 66 20 45.0 5.0 25.0 — 625c 9.0b
ap < 0.05.
bmean.
cmedian.
HCC: hepatocellular carcinoma; CLM: colorectal liver metastase.
Table 3. Long-term outcome after hepatic resection for hepatocellular carcinoma in young and elderly patients.
Author year [ref.] Age (years) No. of patients Cirrhosis (%)
HBV
(%)+
HCV +
(%)
Survival
(months)
5-year survival
(1%)
Ezaki et al. 56–65 44 93.2 — — — 28
1987 [12] ‡ 66 37 67.6 — — — 18
Nagasue et al. £ 50 26 84.6 — — — 49
1993 [19] ‡ 70 32 68.8 9.4 — — 24
Takenaka et al. < 70 229 83.8 18.3 59.0a — 52
1994 [16] ‡ 70 39 79.5 5.1 88.2a — 76
Wu et al. < 80 239 77.8 58.5a — — 59
1999 [15] ‡ 80 21 81.0 28.6a — — 41
Poon et al. < 70 299 48.8 85.9a — 42c 40
1999 [17] ‡ 70 31 25.8 51.6a — 38c 29
Hanazaki et al. < 70 283 54.8 23.7 40.7a 33b 40
2000 [21] ‡ 70 103 45.6 18.4 55.4a 39b 51
Yeh et al. < 70 398 48.9 74.0a 31.8a 28c 32
2004 [18] ‡ 70 34 54.5 25.8a 63.2a 40c 40
Ferrero et al. £ 70 177 100.0 21.4 38.9a — 32
2005 [22] > 70 64 100.0 10.9 60.9a — 49
ap < 0.05.
bmean.
cmedian.
HBV: hepatitis B Virus; HCV: Hepatitis C Virus.
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Pancreatic Resection for Pancreatic and Ampullary Cancer
Approximately 168,000 patients die annually from pancreatic
cancer, which ranks this cancer type as the ninth most common
cause of death from cancer worldwide [11]. The world cancer
statistics demonstrate that most deaths occur in developed na-
tions, with 69,000 deaths (41%) annually in Europe and 28,000
(17%) in North America [11]. The poor prognosis of this disease
is reflected by the high mortality-incidence ratio of 0.98. The risk
to develop pancreatic and ampullary cancer dramatically in-
creases with age, with a median age of 72 years at the time of
diagnosis (Table 1). Thus, as for HCC and colorectal liver
metastases, the epidemiology of the disease combined with the
growth of the older population results in an increasing number of
elderly patients to be considered for pancreatic surgery. Despite
the limited survival benefit of surgery, pancreatico-duodenectomy
remains the standard treatment in the absence of other effective
therapies. Because pancreatic surgery is seen as one of the most
extensive abdominal procedures, many physicians scrutinize the
appropriateness of this operation in geriatric patients.
During the past two decades, pancreatic surgeons have made a
particular effort to investigate the benefit of surgery, mostly for
cancer of the pancreas and the ampullary region (Tables 5 and 6).
Most studies compared perioperative and long–term outcome in
patients younger than 70 years versus those older than 70 years of
age [24, 32–36, 38, 39, 42, 43]. Operative data demonstrated that
intra-operative blood loss and operative times were similar for
younger and older patients, implying that the extent and difficulty
of surgical procedures are independent of age. Also, most studies
demonstrated that pancreatico-duodenectomy can be safely per-
formed in elderly patients, with a mortality rate below 10% (Ta-
ble 5). Only 3 of 14 identified studies reported an unacceptably
Table 4. Long-term outcome after hepatic resection for colorectal liver metastases in young and elderly patients.
Author year [ref.] Age (years) No. of patients Survival (months) 5-year survival (%)
Fong et al. < 70 449 44c 39
1995 [24] ‡ 70 128 40c 35
Brunken et al. < 70 141 — 31
1998 [25] ‡ 70 25 — 46
Brand et al. < 70 126 35a,b 21
2000 [26] ‡ 70 41 22a,b 16
ap < 0.05.
bmean.
cmedian.
Table 5. Preoperative outcome of pancreatic resection in young and elderly patients.
Author year [ref.] Age (years)
No. of
patients
Mortality
rate (%)
Complication
rate (%)
Operative
time (hours)
Blood
loss (ml)
Hospital
stay (days)
Kairaluoma et al. < 70 47 8.5 29.8 — — —
1987 [32] ‡ 70 21 9.5 47.6 — — —
Hannoun et al. < 70 179 10.0 34.6 — — 25.0b
1993 [33] ‡ 70 44 4.5 36.0 — — 22.0b
Kayahara et al. < 70 102 6.9 48.0 9.8a,b 3618a,b —
1994 [34] ‡ 70 28 17.8 53.6 7.6a,b 1735a,b —
Fong et al. < 70 350 4.0 38.3 — — 20.0c
1995 [24] ‡ 70 138 5.8 44.9 — — 20.0c
DiCarlo et al. < 70 85 3.5 32.9 6.7b 700b 16.5b
1998 [35] ‡ 70 33 6.1 39.4 6.2b 750b 17.0b
Magistrelli et al. < 70 73 6.8 27.4 4.2b — 23.5b
1998 [36] ‡ 70 29 0.0 31.0 4.1b — 19.3b
Sohn et al. < 80 681 1.6 39.6 7.0c 650c 16.9a,b
1998 [37] ‡ 80 46 4.3 56.5 6.4c 500c 21.1a,b
Bottger et al. £ 70 243 2.9 39.5 5.7c 1500c 18.0c
1999 [38] > 70 57 5.3 56.1 4.9c 1500c 21.0c
Al Sharaf et al. < 70 47 4.2 46.8 6.0c 2500c 16.0c
1999 [39] ‡ 70 27 7.4 44.4 5.7c 1500c 13.0c
Bathe et al. 65–74 54 3.7 52.0 7.0b 867b 18.0b
2000 [40] ‡ 75 16 25.0 69.0 7.2b 741b 25.0b
Bathe et al. 65–74 47 2.1 38.3 7.2b 973b 15.0b
2001 [41] ‡ 75 19 21.0 57.9 7.5b 750b 25.0b
Hodul et al. < 70 74 1.4 35.1 6.8b 1138b 10.8b
2001 [42] > 70 48 0.0 39.6 6.3b 1071b 11.9b
Richter et al. < 70 426 2.8 21.6 6.0c 1000c 19.0c
2002 [43] < 70 93 3.2 23.6 5.6c 700c 21.5c
Lightner et al. < 75 188 3.2 56.4 — — 15.0b
2004 [44] ‡ 75 30 3.0 70.0 — — 16.0b
ap < 0.05.
bmean.
cmedian.
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high mortality rate of 18%–25% in elderly patients [34, 40, 41].
Elderly patients had also higher complication rates and longer
hospital stay in these studies. However, complication rates and
hospital stay were comparable between the younger and older
populations in the majority of the studies [24, 33–36, 39, 42–44].
Although the elderly population has a higher prevalence of co–
morbidities, American Society of Anesthisiologists (ASA) scores
and co-morbidities were evenly distributed between the two age
groups [36, 39, 40, 42, 43]. Furthermore, patients with ASA grade
IV were either excluded from pancreatic resection or were in the
minority [24, 32–34, 38, 39]. Therefore, careful patient selection
appears to be the key criterion for a favorable perioperative
outcome in elderly patients undergoing pancreatico-duodenec-
tomy.
Regardless of age, the long-term prognosis after pancreatico-
duodenectomy for pancreatic head cancer is discouraging. The
prognosis of patients undergoing pancreatico-duodenectomy for
ampullary tumors is significantly better, but is also associated
with frequent tumor recurrence. As shown in Table 6, the im-
proved patient survival of resected ampullary tumors compared
to pancreatic cancer is present in both the younger and older
populations. Of note, median survival after pancreatico-duo-
denectomy for ampullary and pancreatic cancer was comparable
between younger and older patients in most studies [32, 33, 35,
38, 39, 43]. This was even true for octogenarian patients who
underwent pancreatico-duodenectomy [37]. These data demon-
strate that pancreatico-duodenectomy can be performed safely
in carefully selected elderly patients, and that survival is com-
parable to that observed in younger patients. Therefore, the
decision to perform pancreatic resection should be independent
of chronological age but rather should be based on the best
chance for a curative pancreatic resection in a healthy geriatric
patient.
Radical Resection of Gallbladder Cancer
Gallbladder cancer occurs infrequently in Europe and in the
United States, and has a dismal prognosis. Although gallbladder
cancer is a disease of the elderly, with a median age of more than
70 years at diagnosis (Table 1), only one study was identified
which analyzed the outcome of radical resection for gallbladder
cancer in younger (< 75 years) versus older (‡ 75 years) patients
[45]. In that study, 87 younger patients and 32 elderly patients
underwent extended cholecystectomy for T1–3 gallbladder can-
cer. Clinico–pathological characteristics and perioperative mor-
tality were comparable between the two age groups. The long-
term outcome measured by the 5-year overall survival was 61% in
the elderly group and was not statistically different from that of
younger patients. In contrast, elderly patients (n = 22) who
underwent only simple cholecystectomy for gallbladder cancer
had a poor 5-year overall survival of 14%. Although not primarily
focused on elderly individuals, another large series on curative
resection of gallbladder cancer reported similar mortality and
complication rates among patients <70 years and >70 years of
age [46]. This study failed to identify age as an independent risk
factor of long-term outcome. Despite the poor prognosis of
gallbladder cancer, these data demonstrate that selective elderly
patients might benefit from adequate surgical treatment, and
therefore an aggressive treatment strategy is justified in the el-
derly population.
Table 6. Long-term outcome after pancreatic resection for malignant pancreatic and ampullary tumors in young and elderly patients.
Author year [ref.] Tumor type Age (years) No. of patients
Median
survival (months)
5-year
survival (%)
Kairaluoma et al. Pancreatic cancer < 70 24 8 —
1987 [32] Pancreatic cancer ‡ 70 11 9 —
Ampullary cancer < 70 19 36 58
Ampullary cancer ‡ 70 8 20 25
Hannoun et al. Pancreatic cancer < 70 71 16 19
1993 [35] Pancreatic cancer ‡ 70 21 16 17
Ampullary cancer < 70 39 30 45
Ampullary cancer ‡ 70 10 36 38
Fong et al. Pancreatic, ampullary,
bile duct and duodenal cancer
< 70 350 24a 29
1995 [24] ‡ 70 138 18a 21
DiCarlo et al. Pancreatic cancer < 70 85 16 9
1998 [37] Pancreatic cancer ‡ 70 33 14 —
Sohn et al. Pancreatic cancer < 80 282 17 36b
1998 [37] Pancreatic cancer ‡ 80 25 18 46b
Ampullary cancer < 80 454 20 27
Ampullary cancer ‡ 80 41 32 19
Al Sharaf et al. Pancreatic cancer < 70 14 8 11
1999 [39] Pancreatic cancer ‡ 70 27 10 0
Bathe et al. Ampullary cancer 65–74 54 24 23
2000 [40] Ampullary cancer ‡ 75 16 9 31
Bathe et al. Pancreatic cancer 65–74 47 25a —
2001 [41] Pancreatic cancer ‡ 75 19 11a —
Richter et al. 43 Pancreatic cancer < 70 205 14 —
2002 [43] Pancreatic cancer ‡ 70 42 23 —
Ampullary cancer < 70 106 46 —
Ampullary cancer ‡ 70 28 57 —
ap < 0.05.
b2-year survival rate.
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Resection of Hilar Bile Duct Cancer
Hilar bile duct cancer (Klatskin tumor) represents the most
common form of bile duct cancer [47, 48]. The peak incidence of
this disease occurs within the seventh decade of life (Table 1).
The natural history of untreated Klatskin tumor is dismal, and
results in exceptional 5–year survivors [49]. Although the surgical
management of this disease is difficult and should unquestionably
be limited to specialized centers, radical resection is the only
potential chance for cure. Bile duct resection combined with liver
resection is the most commonly performed curative procedure.
Because a significant proportion of patients are diagnosed at an
advanced age, the questions arise whether this kind of extended
procedure can be safely performed in elderly patients, and whe-
ther such treatment will result in extended survival in the elderly
population. Unfortunately, no published study addressing these
important issues is currently available. Therefore, data on peri-
operative outcome after extended resection of Klatskin tumors
are not available for elderly patients. However, information on
long-term outcome of elderly patients could be extracted from
few series on surgical resection of hilar bile duct cancer. Launois
et al. reported a comparable 5-year survival rate for patients > 70
years (22%) and < 60 years (17%) [50]. Kawasaki et al. found a
similar mean survival in patients ‡ 70 years (32.6 months) and <
70 years (36.6 months) [51]. Despite the absence of age-com-
paring studies, the survival data from these series demonstrate
that elderly patients may benefit from extended resection as much
as young patients do.
Economic Considerations of HPB Surgery in the Elderly
Hepatic and pancreatic resections are undoubtedly among the
most expensive abdominal procedures performed. The forces of
cost control on health care may scrutinize the benefit of extended
resections of HPB tumors in elderly patients. In terms of survival,
the present review illustrates that elderly patients with malignant
liver and pancreas tumors benefit from curative surgery as much
as younger patients do (Tables 3, 4, and 6). Furthermore, the
cost-related variables of geriatric patients such as operative time,
complication rate, and hospital stay were similar to those of their
younger counterparts in most series. These findings alone suggest
that hospital costs for patients undergoing hepatic and pancreatic
resections might not be significantly higher for elderly patients.
This issue was addressed by Vickers et al., who performed a cost-
analysis of pancreatico-duodenectomy in patients ‡ 70 years of
age versus those > 70 years of age [52]. The authors analyzed
separately anesthesia, laboratory, pharmacy, and operating room
costs, as well as the total costs for both age populations. Costs of
anesthesia, laboratory, and pharmacy, as well as total costs, were
comparable between the younger and older population. Inter-
estingly, operating room–related costs were significantly lower for
the elderly population. These favorable findings seem to be
attributable to a careful patient selection in this study as the
preoperative risk profiles were not significantly different between
older and younger patients. Logically, this also resulted in com-
parable perioperative complication profiles for the two age
groups. This illustrates that careful selection of geriatric patients
is of paramount importance, not only for the perioperative and
long-term outcome of hepatic and pancreatic resections but also
for the cost efficiency of these procedures.
Conclusions
The present review demonstrates that extended resections of
malignant HPB tumors can be safely performed in patients over
70 years of age. Despite the lower statistical life expectancy of
elderly patients, the long-term outcome was comparable between
younger patients and the geriatric population. Although the sur-
vival benefit of pancreatic-duodenectomy is limited for patients
with pancreatic cancer, the absence of any other effective therapy
justifies this procedure as the unique curative option not only in
younger patients but also in the elderly. However, the preopera-
tive risk evaluation and the extent of the disease appear to be the
most important criteria for selecting elderly patients who will
benefit from surgery. If the selection process takes these criteria
into account, resections of malignant HPB tumors can be per-
formed in elderly patients without generating higher costs as
compared to younger patients. Therefore, chronological age
alone should not be a contraindication to extended resections of
malignant HPB tumors or a risk factor for inadequate surgical
therapy. Surgery should be denied to elderly patients only after
discussion with expert HPB surgeons.
References
1. National Vital Statistics Reports, vol. 52, No. 14, February 18, 2004.
http://www.cdc.gov/nchs (accessed 2005)
2. http://epp.eurostat.cec.eu.int (accessed 2005)
3. http://www.agingstats.gov (accessed 2005)
4. SEER Cancer Statistics Review 1975–2001. htpp://seer.cancer.gov
(accessed 2005)
5. Fong Y, Sun RL, Jarnagin W, et al. An analysis of 412 cases of
hepatocellular carcinoma at a Western center. Ann. Surg.
1999;229:790
6. Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term sur-
vival following liver resection for hepatic colorectal metastases. Ann.
Surg. 2002;235:759
7. Wetle T. Age as a risk factor for inadequate treatment. J.A.M.A.
1987;258:516
8. Greenﬁeld S, Blanco DM, Elashoff RM, et al. Patterns of care related
to age of breast cancer patients. J.A.M.A. 1987;257:2766
9. http://www.cdc.gov/nchs (accessed 2005)
10. Koziol JA, Zuraw BL, Christiansen SC. Health care consumption
among elderly patients in California: a comprehensive 10-year evalu-
ation of trends in hospitalization rates and charges. Gerontologist
2002;42:207
11. Pisani P, Parkin DM, Bray F, et al. Estimates of the worldwide
mortality from 25 cancers in 1990. Int. J. Cancer 1999;83:18
12. Ezaki T, Yukaya H, Ogawa Y. Evaluation of hepatic resection for
hepatocellular carcinoma in the elderly. Br. J. Surg. 1987;74:471
13. Yanaga K, Kanematsu T, Takenaka K, et al. Hepatic resection for
hepatocellular carcinoma in elderly patients. Am. J. Surg.
1988;155:238
14. Yamamoto K, Takenaka K, Matsumata T, et al. Right hepatic
lobectomy in elderly patients with hepatocellular carcinoma. He-
patogastroenterology 1997;44:514
15. Wu CC, Chen JT, Ho WL, et al. Liver resection for hepatocellular
carcinoma in octogenarians. Surgery 1999;125:332
16. Takenaka K, Shimada M, Higashi H, et al. Liver resection for
hepatocellular carcinoma in the elderly. Arch. Surg. 1994;129:
846
17. Poon RT, Fan ST, Lo CM, et al. Hepatocellular carcinoma in the
elderly: results of surgical and nonsurgical management. Am. J.
Gastroenterol. 1999;94:2460
18. Yeh CN, Lee WC, Jeng LB, et al. Hepatic resection for hepatocellular
carcinoma in elderly patients. Hepatogastroenterology 2004;51:
219
19. Nagasue N, Chang YC, Takemoto Y, et al. Liver resection in the aged
(seventy years or older) with hepatocellular carcinoma. Surgery
1993;113:148
Petrowsky and Clavien: HPB Surgery in the Elderly 1099
20. Lui WY, Chau GY, Wu CW, et al. Surgical resection of hepatocellular
carcinoma in elderly cirrhotic patients. Hepatogastroenterology
1999;46:640
21. Hanazaki K, Kajikawa S, Shimozawa N, et al. Hepatic resection for
hepatocellular carcinoma in the elderly. J. Am. Coll. Surg. 2001;192:38
22. Ferrero A, Vigano L, Polastri R, et al. Hepatectomy as treatment of
choice for hepatocellular carcinoma in elderly cirrhotic patients.
World J. Surg. 2005;29:1101–1105
23. Zieren HU, Muller JM, Zieren J. Resection of colorectal liver
metastases in old patients. Hepatogastroenterology 1994;41:34
24. Fong Y, Blumgart LH, Fortner JG, et al. Pancreatic or liver resection
for malignancy is safe and effective for the elderly. Ann. Surg.
1995;222:426
25. Brunken C, Rogiers X, Malago M, et al. [Is resection of colorectal
liver metastases still justiﬁed in very elderly patients?]. Chirurg
1998;69:1334
26. Brand MI, Saclarides TJ, Dobson HD, et al. Liver resection for
colorectal cancer: liver metastases in the aged. Am. Surg. 2000;66:412
27. Cosenza CA, Hoffman AL, Podesta LG, et al. Hepatic resection for
malignancy in the elderly. Am. Surg. 1995;61:889
28. Nomura F, Ohnishi K, Honda M, et al. Clinical features of hepato-
cellular carcinoma in the elderly: a study of 91 patients older than 70
years. Br. J. Cancer 1994;70:690
29. Namieno T, Kawata A, Sato N, et al. Age-related, different clinico-
pathologic features of hepatocellular carcinoma patients. Ann. Surg.
1995;221:308
30. Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of
colorectal carcinoma metastases to the liver. A prognostic scoring
system to improve case selection, based on 1568 patients. Association
Franc¸aise de Chirurgie. Cancer 1996;77:1254
31. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting
recurrence after hepatic resection for metastatic colorectal cancer:
analysis of 1001 consecutive cases. Ann. Surg. 1999;230:309
32. Kairaluoma MI, Kiviniemi H, Stahlberg M. Pancreatic resection for
carcinoma of the pancreas and the periampullary region in patients
over 70 years of age. Br. J. Surg. 1987;74:116
33. Hannoun L, Christophe M, Ribeiro J, et al. A report of forty-four
instances of pancreaticoduodenal resection in patients more than
seventy years of age. Surg. Gynecol. Obstet. 1993;177:556
34. Kayahara M, Nagakawa T, Ueno K, et al. Pancreatic resection for
periampullary carcinoma in the elderly. Surg. Today 1994;24:229
35. DiCarlo V, Balzano G, Zerbi A, et al. Pancreatic cancer resection in
elderly patients. Br. J. Surg. 1998;85:607
36. Magistrelli P, Masetti R, Coppola R, et al. Pancreatic resection for
periampullary cancer in elderly patients. Hepatogastroenterology
1998;45:242
37. Sohn TA, Yeo CJ, Cameron JL, et al. Should pancreaticoduodenec-
tomy be performed in octogenarians? J. Gastrointest. Surg. 1998;2:
207
38. Bottger TC, Engelmann R, Junginger T. Is age a risk factor for major
pancreatic surgery? An analysis of 300 resections. Hepatogastroente-
rology 1999;46:2589
39. Al-Sharaf K, Andren-Sandberg A, Ihse I. Subtotal pancreatectomy
for cancer can be safe in the elderly. Eur. J. Surg. 1999;165:230
40. Bathe OF, Levi D, Caldera H, et al. Radical resection of periampul-
lary tumors in the elderly: evaluation of long-term results. World J.
Surg. 2000;24:353
41. Bathe OF, Caldera H, Hamilton KL, et al. Diminished beneﬁt from
resection of cancer of the head of the pancreas in patients of advanced
age. J. Surg. Oncol. 2001;77:115
42. Hodul P, Tansey J, Golts E, et al. Age is not a contraindication to
pancreaticoduodenectomy. Am. Surg. 2001;67:270
43. Richter A, Niedergethmann M, Lorenz D, et al. Resection for cancers
of the pancreatic head in patients aged 70 years or over. Eur. J. Surg.
2002;168:339
44. Lightner AM, Glasgow RE, Jordan TH, et al. Pancreatic resection in
the elderly. J. Am. Coll. Surg. 2004;198:697
45. Onoyama H, Ajiki T, Takada M, et al. Does radical resection improve
the survival in patients with carcinoma of the gallbladder who are 75
years old and older? World J. Surg. 2002;26:1315
46. Fong Y, Jarnagin W, Blumgart LH. Gallbladder cancer: comparison
of patients presenting initially for deﬁnitive operation with those
presenting after prior noncurative intervention. Ann. Surg.
2000;232:557
47. Klatskin G. Adenocarcinoma of the hepatic duct at its bifurcation
within the porta hepatis. An unusual tumor with distinctive clinical
and pathological features. Am. J. Med. 1965;38:241
48. Nakeeb A, Pitt HA, Sohn TA, et al. Cholangiocarcinoma. A spectrum
of intrahepatic, perihilar, and distal tumors. Ann. Surg. 1996;224:
463
49. Farley DR, Weaver AL, Nagorney DM. ‘‘Natural history’’ of unre-
sected cholangiocarcinoma: patient outcome after noncurative inter-
vention. Mayo Clin. Proc. 1995;70:425
50. Launois B, Terblanche J, Lakehal M, et al. Proximal bile duct cancer:
high resectability rate and 5-year survival. Ann. Surg. 1999;230:
266
51. Kawasaki S, Imamura H, Kobayashi A, et al. Results of surgical
resection for patients with hilar bile duct cancer: application of ex-
tended hepatectomy after biliary drainage and hemihepatic portal vein
embolization. Ann. Surg. 2003;238:84
52. Vickers SM, Kerby JD, Smoot TM, et al. Economics of pancreato-
duodenectomy in the elderly. Surgery 1996;120:620
1100 World J. Surg. Vol. 29, No. 9, September 2005
